Cannara Biotech Reports 35% Revenue Growth in Q2 2025

Cannara Biotech reported record-breaking results for Q2 2025, achieving net revenues of C$26.6 million—a 35% year-over-year increase—driven by national expansion, premium brand growth, and strong consumer loyalty. The company turned a profit with net income of $3.3 million, reversing a loss from the previous year, and marked its sixteenth consecutive quarter of positive adjusted EBITDA, which more than doubled to $7.1 million. Market share rose to 3.9% nationally, with significant gains in Quebec (where Cannara holds the third-largest market share at 12.8%), Ontario, and Alberta. Operationally, Cannara expanded its annual production capacity to nearly 40,000 kg by activating new cultivation zones and continues to invest in scaling output and innovation, including launching over 20 new products in 2025. The company’s disciplined execution and focus on brand development have positioned it as a leader in Canada's cannabis industry, with management optimistic about continued growth. These achievements suggest a strong outlook both for Cannara and for investor confidence in the maturing cannabis sector.